Bal Pharma Share Price Today | Stock Price & Bal Pharma Share Screener
As of October 1, 2026, the live Bal Pharma share price (NSE: BALPHARMA) is ₹105.74 on NSE and ₹107.60 on BSE, down 3.46% from the previous close, with shares trading between ₹104.51 and ₹110.00 in today's trading session, and a 52-week range of ₹60.42–₹114.45. Check BALPHARMA 52-week high low for the annual price range and momentum. Use the Bal Pharma stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Bal Pharma opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹84 and net income of ₹4, with EBITDA of ₹10, an operating margin of 13.0% and a profit margin of 4.8%.
Bal Pharma Share Price Chart
Track the current stock price of Bal Pharma with an interactive chart. Analyse BALPHARMA share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Bal Pharma stock quote in one place.
The quote of ₹105.74 sits between the 52-week low of ₹60.42 and the 52-week high of ₹114.45, and the latest session moved -3.46% from the previous close.
Bal Pharma Company Profile - Fundamental Screener
Screen Bal Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for BALPHARMA shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE083D01012.
Company Details
Classification
Identifiers and Leadership
Bal Pharma Balance Sheet Screener
Screen BALPHARMA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹376, up from ₹336 in 2025.
Latest statistics put total assets at ₹376 and shareholder funds at ₹82, with a leverage ratio of 1.94.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 376 | 336 | 320 | 313 | 261 | 240 | 238 | 261 | 260 | 233 |
| Current Assets | 262 | 235 | 234 | 228 | 185 | 164 | 157 | 183 | 185 | 165 |
| Fixed Assets | 98 | 87 | 80 | 77 | 67 | 69 | 71 | 70 | 72 | 60 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 44 | 39 | 45 | 40 | 36 | 34 | 34 | 38 | 46 | 30 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 82 | 77 | 72 | 64 | 59 | 53 | 45 | 60 | 60 | 60 |
| Share Capital | 16 | 16 | 16 | 16 | 15 | 15 | 14 | 14 | 14 | 14 |
| Reserves & Surplus | 66 | 62 | 56 | 48 | 43 | 38 | 38 | 53 | 51 | 48 |
Bal Pharma Income Statement Screener - Profit & Revenue Analysis
Screen Bal Pharma income statement and profit fundamentals. Analyze BALPHARMA quarterly results. Bal Pharma reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Mar, revenue was ₹84 and net profit was ₹4, equal to earnings per unit of ₹2.26, at an operating margin of 13%.
In that period expenses were ₹74, interest cost ₹4 and tax ₹0. The next period listed, 2026-Jun, shows revenue of ₹89 and net profit of ₹1.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 84 | 89 | 83 | 67 | 75 | 88 | 97 | 75 | 74 | 74 | 83 | 71 | 93 | 82 | 78 |
| Expenses | 74 | 81 | 74 | 60 | 68 | 78 | 85 | 68 | 66 | 65 | 74 | 64 | 85 | 74 | 71 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 10 | 8 | 9 | 7 | 7 | 10 | 12 | 7 | 8 | 8 | 8 | 7 | 8 | 8 | 7 |
| Operating Profit % | 13.00% | 9.00% | 9.00% | 9.00% | 8.00% | 11.00% | 10.00% | 9.00% | 10.00% | 11.00% | 10.00% | 9.00% | 8.00% | 10.00% | 5.00% |
| Depreciation | 3 | 3 | 2 | 3 | 2 | 3 | 2 | 2 | 3 | 3 | 2 | 3 | 2 | 3 | 2 |
| Interest | 4 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 4 | 3 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 3 | 1 | 3 | 0 | 1 | 2 | 6 | 1 | 1 | 1 | 2 | 0 | 2 | 1 | 2 |
| Tax | 0 | 0 | -3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Net Profit | 4 | 1 | 5 | 0 | 1 | 2 | 6 | 0 | 1 | 1 | 2 | 0 | 1 | 1 | 2 |
| EPS | 2.26 | 0.71 | 3.40 | 0.13 | 0.45 | 1.12 | 3.73 | 0.16 | 0.65 | 0.33 | 1.03 | 0.06 | 0.62 | 0.54 | 1.33 |
Bal Pharma Cash Flow Screener - Liquidity Fundamentals
Screen BALPHARMA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2025-March, operating activities generated ₹20, and net cash flow was an outflow of ₹2.
Over the same period, investing activities used ₹15 and financing activities used ₹8.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 20 | 23 | -2 | 27 | 22 | 23 | 8 | 1 | 6 | -19 |
| Investing Activities | -15 | -19 | -22 | -10 | -6 | -5 | -8 | -4 | -8 | -14 |
Financing and Net Cash | ||||||||||
| Financing Activities | -8 | -1 | 24 | -17 | -17 | -20 | 0 | 4 | -6 | 32 |
| Net Cash Flow | -2 | 3 | 0 | 0 | 0 | -2 | 0 | 1 | -8 | -1 |
Bal Pharma Shareholding Pattern Screener
See Bal Pharma shareholding pattern with promoter, FII, and DII holdings. Check Bal Pharma promoter holding and ownership changes for BALPHARMA on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 50.86%, foreign institutions 0.14%, domestic institutions 0.00% and the public 32.84%, spread across 15,214 shareholders.
The shareholder count was 15,214 in 2026-Mar, compared with 14,974 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 50.86% | 50.86% | 50.86% | 50.86% | 50.86% | 50.86% | 51.23% | 51.23% |
Institutional Investors | ||||||||
| FII Holding | 0.14% | 0.15% | 0.14% | 0.15% | 0.22% | 0.14% | 0.13% | 0.13% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 32.84% | 32.86% | 32.49% | 32.41% | 32.97% | 33.02% | 32.15% | 32.36% |
| Other Holding | 16.16% | 16.13% | 16.51% | 16.58% | 15.94% | 15.99% | 16.49% | 16.28% |
| Shareholder Count | 15,214 | 14,974 | 15,723 | 15,826 | 15,774 | 15,520 | 14,772 | 15,014 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Bal Pharma. Bal Pharma dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹1.20 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹1.20 and ₹1.20 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹1.20 | 1.99% |
| 2024-March | ₹1.20 | 1.43% |
| 2023-March | ₹1.00 | 1.10% |
| 2022-March | ₹1.00 | 1.55% |
| 2021-March | ₹1.00 | 0.93% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹1.00 | 3.13% |
| 2018-March | ₹1.00 | 1.43% |
| 2017-March | ₹1.00 | 1.30% |
Bal Pharma Stock Index Membership - Nifty & Sensex
See which indices include Bal Pharma stock. Check BALPHARMA index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Bal Pharma Market Events Screener - Corporate Actions
Get Bal Pharma corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Bal Pharma stock events that may affect BALPHARMA share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Annual General Meeting dated September 24, 2026, with a record date of September 24, 2026.
It is followed by Dividend dated September 17, 2026 and Quarterly Result Announcement dated August 12, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-24 | 2026-09-24 | Annual General Meeting | NA | 24.87% |
| 2026-09-17 | 2026-09-17 | Dividend | ₹ 1.20 /share | 10.22% |
| 2026-08-12 | 2026-08-12 | Quarterly Result Announcement | NA | -1.12% |
| 2026-05-27 | 2026-05-27 | Quarterly Result Announcement | NA | 17.37% |
| 2026-02-11 | 2026-02-11 | Quarterly Result Announcement | NA | 7.85% |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | -1.70% |
| 2025-09-25 | 2025-09-25 | Annual General Meeting | NA | -9.36% |
| 2025-09-18 | 2025-09-18 | Dividend | ₹ 1.20 /share | -6.50% |
| 2025-08-11 | 2025-08-11 | Quarterly Result Announcement | NA | -3.59% |
| 2025-05-29 | 2025-05-29 | Quarterly Result Announcement | NA | -6.14% |
| 2025-02-13 | 2025-02-13 | Quarterly Result Announcement | NA | -12.62% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -7.93% |
| 2024-09-25 | 2024-09-25 | Annual General Meeting | NA | 14.26% |
| 2024-09-17 | 2024-09-19 | Dividend | ₹ 1.20 /share | 31.47% |
| 2023-12-21 | 2023-12-21 | Extraordinary General Meeting | NA | -10.17% |
Bal Pharma Competitors Screener - Peer Stocks Comparison
Screen BALPHARMA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 432,120 | 35.84 | 61,674 | 12.69% | 11,565 | 36.68 |
| Divis Laboratories | 245,532 | 84.36 | 11,067 | 13.95% | 2,568 | 51.70 |
| Torrent Pharmaceuticals | 181,333 | 84.01 | 13,886 | 20.34% | 2,138 | 41.12 |
| Zydus Life Science | 114,284 | 24.88 | 27,658 | 17.64% | 5,026 | 47.64 |
| Cipla | 108,576 | 32.42 | 29,045 | 2.24% | 3,870 | 34.78 |
| Laurus Labs | 107,198 | 98.56 | 6,868 | 22.01% | 890 | 58.70 |
| Mankind Pharma | 104,707 | 50.48 | 14,636 | 14.85% | 1,938 | 61.75 |
| Dr Reddys Laboratories | 100,679 | 31.47 | 35,059 | 3.90% | 4,158 | 53.84 |
| Aurobindo Pharma | 96,479 | 25.97 | 34,145 | 5.56% | 3,503 | 50.30 |
| Lupin | 92,885 | 16.71 | 29,039 | 26.75% | 5,356 | 31.59 |
Bal Pharma Company Announcements - News & Reports Screener
Screen BALPHARMA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated September 27, 2026.
The next most recent announcements are dated September 27, 2026 and September 27, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-09-27 | Announcement under Regulation 30 (LODR)-Change in Directorate | - |
| 2026-09-27 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-09-27 | Closure of Trading Window | - |
| 2026-09-26 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-09-10 | Clarification Regarding Movement In Price | - |
| 2026-09-10 | Clarification sought from Bal Pharma Ltd | - |
| 2026-09-07 | Announcement under Regulation 30 (LODR)-Allotment | - |
| 2026-08-27 | Intimation Of Record Date For Final Dividend | - |
| 2026-08-26 | Reg. 34 (1) Annual Report. | - |
| 2026-08-26 | Bal Pharma Limited - Notice Of AGM | - |
| 2026-08-26 | Intimation - 39Th AGM Scheduled On 24Th September 2026 | - |
| 2026-08-25 | Clarification With Respect To Tentative Timeline For Utilization Of Net Proceeds Of Preferential Issue | - |
| 2026-08-13 | Newspaper Publications - Unaudited Financial Results 30Th June 2026 And IEPF Notice | - |
| 2026-08-12 | Financial Result For The Quarter End 30Th June 2026 | - |
| 2026-08-12 | Board Meeting Outcome for Outcome Of Board Meeting Held On Wednesday August 12 2026 | - |
| 2026-08-10 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | - |
| 2026-08-10 | Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot | - |
| 2026-08-05 | Board Meeting Intimation for Considering Inter-Alia The Unaudited (Standalone And Consolidated) Financial Statements Of The Company For The First Quarter Ended 30Th June 2026 And Other General Business Matters | - |
| 2026-07-30 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 : Intimation Regarding Notice Of Postal Ballot | - |
| 2026-07-23 | Intimation Regarding Corrigendum To The Postal Ballot Notice | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹105.74, within a 52-week range of ₹60.42 to ₹114.45. The P/E ratio is 23.21 and the P/B ratio is 2.04, with earnings per unit of ₹3.95. Market capitalisation stands at ₹168.30 Cr and the dividend yield is 1.14%. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 6, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.